| Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma FL Locke, DB Miklos, CA Jacobson, MA Perales, MJ Kersten, OO Oluwole, ... New England Journal of Medicine 386 (7), 640-654, 2022 | 455 | 2022 |
| Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial F Morschhauser, H Tilly, A Chaidos, P McKay, T Phillips, S Assouline, ... The Lancet Oncology 21 (11), 1433-1442, 2020 | 298 | 2020 |
| Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma MR Bishop, M Dickinson, D Purtill, P Barba, A Santoro, N Hamad, K Kato, ... New England Journal of Medicine 386 (7), 629-639, 2022 | 226 | 2022 |
| Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy CFM Hughes, A Khot, C McCormack, S Lade, DA Westerman, R Twigger, ... Blood, The Journal of the American Society of Hematology 125 (1), 71-81, 2015 | 203 | 2015 |
| Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect M Dickinson, RW Johnstone, HM Prince Investigational new drugs 28, 3-20, 2010 | 164 | 2010 |
| Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial NH Fowler, M Dickinson, M Dreyling, J Martinez-Lopez, A Kolstad, ... Nature medicine 28 (2), 325-332, 2022 | 136 | 2022 |
| A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma CY Cheah, KE Herbert, K O'rourke, GA Kennedy, A George, PL Fedele, ... British journal of cancer 111 (6), 1072-1079, 2014 | 136 | 2014 |
| Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase … J Kuruvilla, R Ramchandren, A Santoro, E Paszkiewicz-Kozik, ... The Lancet Oncology 22 (4), 512-524, 2021 | 118 | 2021 |
| Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma M Dickinson, D Ritchie, DJ DeAngelo, A Spencer, OG Ottmann, T Fischer, ... British journal of haematology 147 (1), 97-101, 2009 | 115 | 2009 |
| Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre‐transplant FDG‐PET scan following salvage chemotherapy M Dickinson, R Hoyt, AW Roberts, A Grigg, JF Seymour, HM Prince, ... British journal of haematology 150 (1), 39-45, 2010 | 97 | 2010 |
| Romidepsin for cutaneous T-cell lymphoma HM Prince, M Dickinson Clinical Cancer Research 18 (13), 3509-3515, 2012 | 90 | 2012 |
| A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma SJ Harrison, H Quach, E Link, JF Seymour, DS Ritchie, S Ruell, J Dean, ... Blood, The Journal of the American Society of Hematology 118 (24), 6274-6283, 2011 | 90 | 2011 |
| Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial SS Neelapu, M Dickinson, J Munoz, ML Ulrickson, C Thieblemont, ... Nature medicine 28 (4), 735-742, 2022 | 88 | 2022 |
| Azacitidine with or without eltrombopag for first-line treatment of intermediate-or high-risk MDS with thrombocytopenia M Dickinson, H Cherif, P Fenaux, M Mittelman, A Verma, MSO Portella, ... Blood, The Journal of the American Society of Hematology 132 (25), 2629-2638, 2018 | 80 | 2018 |
| Interim report from a phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory B‐cell non‐Hodgkin Lymphomas F Morschhauser, G Salles, P McKay, H Tilly, A Schmitt, J Gerecitano, ... Hematological Oncology 35, 24-25, 2017 | 79 | 2017 |
| Limited role for surveillance PET–CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy CY Cheah, MS Hofman, M Dickinson, A Wirth, D Westerman, SJ Harrison, ... British journal of cancer 109 (2), 312-317, 2013 | 78 | 2013 |
| Acute myeloid leukemia patients’ clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts B Reis, L Jukofsky, G Chen, G Martinelli, H Zhong, WV So, MJ Dickinson, ... Haematologica 101 (5), e185, 2016 | 77 | 2016 |
| Phase 1/1b study of RG7388, a potent MDM2 antagonist, in acute myelogenous leukemia (AML) patients (Pts) K Yee, G Martinelli, N Vey, MJ Dickinson, K Seiter, S Assouline, ... Blood 124 (21), 116, 2014 | 67 | 2014 |
| Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes P Yeh, M Dickinson, S Ftouni, T Hunter, D Sinha, SQ Wong, R Agarwal, ... Blood, The Journal of the American Society of Hematology 129 (12), 1685-1690, 2017 | 58 | 2017 |
| Peripheral blood CD34+ cell enumeration as a predictor of apheresis yield: an analysis of more than 1,000 collections P Gambell, K Herbert, M Dickinson, K Stokes, M Bressel, D Wall, ... Biology of Blood and Marrow Transplantation 18 (5), 763-772, 2012 | 53 | 2012 |
HM Prince在 petermac.org 的电子邮件经过验证
